Knowledge • News • Insights

In Partnership With

MICHBIO: BioLink 11.16.26 – Stay Informed & Connected

Michigan Business Network: MichBIO

December 9, 2026 | 5:00-7:00 PM

Ann Arbor

Breakthrough science alone is no longer enough to ensure success. Regulatory uncertainty, shifting policies, capital constraints, and evolving investor expectations are creating new challenges for emerging life science companies.

Join us at BioArbor® on December 9 for a timely fireside conversation featuring Ipsita Smolinski, Managing Director of Capitol Street and faculty member at Georgetown University, moderated by Tony Dace, Vice President – Life Sciences at J.P. Morgan.

Drawing on experience across Wall Street and Washington, the discussion will explore investor priorities, policy shifts, emerging opportunities, and strategies to help life science entrepreneurs navigate an increasingly complex landscape.

REGISTER TODAY

MichBio is Heading to J.P. Morgan Healthcare Week—

Let Us Take You Along

MichBio will be in San Francisco for J.P. Morgan Healthcare Week, January 11–14, 2027, connecting with industry leaders, investors, and potential partners.

Can’t attend? Let MichBio help you make connections.

MichBio invites eligible members to leverage our presence at JPM Healthcare Week through pitch deck reviews and partnering meeting support.

This opportunity is designed for companies with an active product or technology portfolio, a solid business plan, and an interest in licensing or partnering, particularly those developing therapeutics, diagnostics, or health technologies.

Deadline to request partnering support: December 4, 2026, at 5:00 PM ET.

REQUEST PARTNERING SUPPORT

Below are upcoming industry events. Click here to view all events.

MichBio members receive an additional discount on Partner Events.
Deadline dates do apply and are listed on the discount page. Login to your membership account to access discount codes/directions.

 

INDUSTRY EVENT

Nucleate Michigan – MBVF Seminar #2

November 16, 2026

Ann Arbor

PARTNER EVENT

GBG Non-Dilutive Funding Webinar

November 19, 2026

Virtual

INDUSTRY EVENT

Nucleate Michigan – MBVF Seminar #3

December 2, 2026

Ann Arbor

MB WEBINAR

AI & IP Perspectives from Abroad

December 9, 2026

Ann Arbor, MI

MB NETWORKING EVENT

BioArbor®

December 9, 2026

Ann Arbor, MI

MB NETWORKING EVENT

BioMixer™ Grand Rapids

December 10, 2026

Grand Rapids, MI

PARTNER EVENT

GBG Non-Dilutive Funding Webinar

December 17, 2026

Virtual

PARTNER EVENT

MB NETWORKING EVENT

State Bio Friends Reception at JPM 2027

January 10, 2027

San Francisco, CA

PARTNER EVENT

2027 Biotech Showcase™

January 11-13, 2027

San Francisco, CA

MichBio Members eligible for $200 savings, click here.

MB NETWORKING EVENT

BioMixer™ Detroit

February 17, 2027

Detroit, MI

MB NETWORKING EVENT

BioArbor®

March 10, 2027

Ann Arbor, MI

MB NETWORKING EVENT

BioMixer™ Lansing

March 18, 2027

Lansing

MB SIGNATURE EVENT

2027 Michigan Patient Advocacy Forum™

March 25, 2027

Virtual

MB SIGNATURE EVENT

2027 Michigan Drug Discovery & Development Symposium™

May 24, 2027

Ann Arbor, MI

PARTNER EVENT

BIO International Convention

June 7-10, 2027

Philadelphia, PA

MichBio Members eligible for $200 savings, click here.

 

VIEW FULL EVENT CALENDAR

Cayman Chemical Files Psilocybin Drug Master File with FDA

Cayman Chemical has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration for its pharmaceutical-grade psilocybin, supporting researchers and drug developers investigating its potential therapeutic applications. The filing provides regulatory documentation related to manufacturing, quality and controls, helping streamline the development process for organizations pursuing clinical research involving psilocybin.

 

>> LEARN MORE

 

Vertex Pharmaceuticals Named One of BioSpace’s Best Places to Work

Vertex Pharmaceuticals has been named one of BioSpace’s Best Places to Work for 2027. The recognition highlights the company’s workplace culture, commitment to employee development and emphasis on collaboration and scientific innovation. Vertex credits its employees and shared values for creating an environment that supports groundbreaking research and the development of transformative medicines.

>> LEARN MORE

 

Regeneron Recognized Among BioSpace’s Best Places to Work for Seventh Consecutive Year

Regeneron has been named one of BioSpace’s Best Places to Work for 2027 in the Large Employer category. This marks the seventh consecutive year the company has received the distinction, having been recognized every year since the award’s inception. The honor reflects Regeneron’s commitment to fostering a culture of scientific innovation, professional growth and collaboration.

>> LEARN MORE

 

Honigman Recognized in 2026 Best Law Firm Rankings

Honigman has earned national and regional recognition in the 2026 Best Law Firms rankings, with the firm ranked nationally in 23 practice areas and regionally in 97. Its Real Estate and Insurance Law practices received National Tier 1 rankings for the third and sixth consecutive years, respectively. The recognition highlights Honigman’s breadth of legal expertise and continued commitment to serving clients across a range of industries.


>> LEARN MORE

 
PhRMA

PhRMA Announces Two Leadership Appointments

The Pharmaceutical Research and Manufacturers of America (PhRMA) has announced two additions to its leadership team. Kristi Way joins as Senior Executive Vice President, Head of Strategy and Operations, bringing extensive experience in government, business and strategic leadership. Michael Woody has been promoted to Executive Vice President, Federal Advocacy, drawing on more than 20 years of federal health policy experience. The appointments support PhRMA’s efforts to advance biopharmaceutical innovation and patient access to medicines.

>> LEARN MORE

 

Amgen Presents New Cardiovascular Research at AHA Scientific Sessions

Amgen presented new research at the American Heart Association’s 2026 Scientific Sessions demonstrating the potential cost-effectiveness of intensive LDL cholesterol lowering in patients at high cardiovascular risk who have not experienced a heart attack or stroke. The findings contribute to growing evidence supporting earlier, more intensive cholesterol management to help reduce cardiovascular risk and inform treatment decisions.


>> LEARN MORE

 
Merck

Merck Presents New Phase 2b Data for Investigational Liver Disease Treatment

Merck has presented new Phase 2b clinical trial data for an investigational treatment for metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease. The findings, presented at The Liver Meeting 2026 and published in The Lancet, contribute to ongoing research into potential treatment options for a condition affecting an estimated 5% of the global population.


>> LEARN MORE

 

MSU Advances Research in Materials Science and Computational Medicine

Michigan State University is celebrating two significant research developments. Chengcheng Fang, assistant professor of chemical engineering and materials science, was selected for the U.S. Department of Energy’s 2026 Early Career Research Program to advance research into complex oxide materials. Meanwhile, MSU and Corewell Health have welcomed computational medicine expert Paul Macklin, PhD, who will lead MSU’s new Division of Computational Medicine and advance the use of computer simulations to study cancer and potential treatments.


>> LEARN MORE ABOUT FENG
>> LEARN MORE ABOUT MACKLIN

FEDERAL UPDATE

MichBio Calls for Changes to Proposed Biotech Investment Restrictions

MichBio has joined a national coalition urging federal policymakers to reconsider portions of proposed COINS Act regulations that could affect biotechnology investments and international partnerships. While supporting strong national security safeguards, the coalition is raising concerns about restrictions that could disrupt licensing agreements, financing, and drug development. Learn what the proposed rules could mean for Michigan’s emerging biotech companies and how industry stakeholders can make their voices heard.

READ MORE

FEDERAL UPDATE

BIO and California Associations Challenge GLOBE Drug Pricing Model

BIO and two California life sciences associations have filed a federal lawsuit challenging Medicare’s GLOBE drug pricing model, arguing that its reliance on international price benchmarks could discourage investment in new medicines. The legal challenge raises important questions about drug affordability, patient access, and the future of biotechnology innovation. Learn what’s at stake for emerging biotech companies and how the outcome could affect financing and development strategies.

 

READ MORE

What's Hot

Get the latest news from MBN right in your inbox

Sign up for our newsletter and never miss a beat.